Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Terminated 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 6Sarcoma 4CNS 3Breast 3Plasma cell 2Dermatologic 2Thoracic 1Gynecologic 1

Conditions

Melanoma 2Recurrence 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Propranolol × Dermatologic × Clear all
NCT01988831 2019-05-10

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

University Hospital, Geneva

Phase 2 Suspended
450 enrolled
Dermatologic

Melanoma, Recurrence

NCT01705392 2017-02-24

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Haukeland University Hospital

Phase 2 Terminated
2 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡